Vetoquinol and Zenoaq are pleased to announce that they have mutually agreed to dissolve their joint venture Vetoquinol Zenoaq Co., Ltd. The joint venture is scheduled to be dissolved in January 2022.

●Press Release by Vetoquinol SA

ZENOAQ is honored to be the Associate Partner for the annual Animal Health Innovation Asia, which will be held on October 19-20. This virtual forum will bring you a unique opportunity to gain insight into industry trends, new opportunities for innovation, and new partnerships from start-ups to global companies. This year, it is stretched to Asia Pacific, allowing for a broader exchange of ideas.

We hope to see you and your team at the forum!

Get 10% discount - Click here and type 'ZENOAQ10' at the checkout

With establishment of the renewed management philosophy and vision 2030, we made a short movie reflecting the brand concept with condensed essence of our principles.

ZENOAQ Brand Movie　'Gazing at the Future'

From February 22nd to 23rd, ZENOAQ participated as a Gold Digital Innovation Partner for the Animal Health Innovation Europe 2021. ZENOAQ sincerely thanks everyone involved and all the attendees for creating such an enabling event. The ZENOAQ team is looking forward to meeting you again soon.

NIPPON ZENYAKU KOGYO CO., LTD. and ZENOAQ RESOURCE CO., LTD. announced reorganization of entire group company from FY2021 in order to stabilize management and expand business. We will establish new business holding company "ZENOAQ HOLDINGS CO., LTD." and affiliate NIPPON ZENYAKU KOGYO CO., LTD., which mainly focuses on veterinary drugs, and ZENOAQ RESOURCE CO., LTD. (to be renamed as ZENOGEN PHARMA CO., LTD.), which mainly focuses on human medicine as wholly owned subsidiaries.

Press Release_【ZENOAQ】ZENOAQ Group to Change to Holding Company Structure_210216.pdf

Dear valued customers and business partners,　　　　　　　　　　　　　　　　　　　

We would like to express our heartfelt sympathy to all those who are affected by the Fukushima Offshore Earthquake of Saturday, February 13, 2021. We would also like to express our sincere gratitude to the many people who have expressed their concern and sympathy to ZENOAQ, headquartered in Koriyama City, Fukushima Prefecture.
The damage situation and the corresponding actions we have taken are as follows;

1. Safety of employees and their families
We have confirmed that all of our employees and their families are safe, but some have reported damage to their homes.

2. Damage to infrastructure, facilities and equipment
Electricity and water are being supplied, but some of the LNG supply pipes have been damaged, and boilers and heaters are out of service at facilities that use them. All information systems are operating normally. We are accepting orders through "Vets Direct" and the call center.
We are currently checking the extent of any damage at our factories. Operations are currently suspended. Our research facilities are also in a similar situation, but there is no problem with the surrounding environment as the biohazard facilities have been sealed off and the air conditioning turned off as a precaution.

3. Order Shipments
Although there was some toppling of shipments at the product warehouses, our employees were able to restore the warehouses to their original condition yesterday. Therefore, we are able to ship the products you ordered as usual, without delay. We have not received any notification from the logistics company regarding the suspension or change in deliveries.

There are still concerns that aftershocks will continue to occur. We will inform you of any changes in the situation as they occur.

Sincerely,

ZENOAQ is honored to be the Gold Digital Innovation Partner for the sixth annual Animal Health Innovation Europe, which will be held on February 22-23. This year's virtual format is an exciting opportunity to connect with colleagues from around the world through roundtables, interactive panels, workshops, networking roulette and more.

We hope to see you and your team at the forum!

ZENOAQ is honored to be the Platinum Digital Innovation Partner for the 2020 Animal Health Innovation Asia, which will be held in November 24-26.

We hope to see you and your team at the forum soon.

■Animal Health Innovation ASIA

The ongoing COVID-19 outbreak is an unprecedented public health crisis creating hardships for communities everywhere.

ZENOAQ joins HealthforAnimals as a board member. HealthforAnimals and our Members are taking responsibility in the response.

This document outlines where we are acting now to support the animal health community and wider world in this difficult time. We are committed to building on this work, continuing to help those around us and working together to help with the eventual recovery.

covid-19_how_we_are_acting.pdf

Dear our valuable customers and business partners,

We would like to express our heartfelt sympathy to all those who have been affected by COVID-19 infection and hope for a speedy recovery and closure of the disease expansion.

ZENOAQ will proactively respond to this situation to prevent the spread of infection, giving the highest priority to the safety of customers, business partners and employees.

We would like to inform you of our response at this time.
Thank you very much for your understanding.

1. About expatriation and overseas business trips
In response to the spread of COVID-19, the company has been implementing thorough infection prevention measures for employees stationed overseas and local employees since January 29, 2020. In light of the shortage of goods in China at initial stage, we have sent masks from Japan to all of our offices to support them. Overseas travel to other areas, including infected areas, has also been cancelled.

2. Response to employees
We voluntarily refrain from participating in domestic and overseas business trips, external training, and social gatherings where an unspecified number of people gather. We are instructed to take thorough infection prevention measures, check for changes in physical condition, and if symptoms are observed, contact a specialist consultation service and suspend work. We supply supplies from our head office to offices where masks, disinfectants, and other supplies are difficult to obtain. Large internal meetings, etc., are also prohibited for the time being.
Please note that the ceremony for issuing the new employee's letter of resignation will be held with a minimum number of people, after taking sufficient measures to prevent infection.

3. External Activities
In consideration of the infection situation in Japan, all external events hosted by our company are cancelled or postponed for the time being. In our sales activities, we disinfect our sales vehicles and take thorough measures to prevent infection among our staff members and shorten business meeting times as much as possible.

4. Supply of products
In order to ensure the continuity of our customers' business, we make various adjustments to ensure that the supply of our products is not disrupted. If there is an impact on procurement, we will do our best to minimize it in the future.

5. Recommendations for a variety of work styles
As a result of the Japanese government's decision to close schools, employees who wish to work telecommuting are required to do so. Network security rules will be strictly adhered to during enforcement. In addition, if an employee has no choice but to take a leave of absence due to this case, special leave (paid leave) will be granted to those employees with little paid leave remaining.
If employees use public transportation, we encourage them to take advantage of staggered working hours.

Sincerely,

Toshikazu Fukui
President
ZENOAQ

ZENOAQ, as a member of HealthforAnimals, announces HealthforAnimals' statement on COVID-19.

HealthforAnimals Statement on COVID-19.pdf

On November 6th and 7th, ZENOAQ participated as the headline partner in the 4th edition of Animal Health Innovation Asia.

Held for the 1st time in Japan, the event brought together over 80 companies to exchange views on the evolution of the Animal Health industry in Asia and especially Japan. Local and international businesses, start-ups and universities alike were represented making AHIA Tokyo 2019 a favorable environment for positive interactions and business developments. During the 2 days conference, Dr. Mark Micallef (ZENOAQ) welcomed as the chairperson over 20 speakers who brought talks that ranged from market trends, challenges in disease prevention, the ASF crisis, digitization of veterinary practice to opportunities of aquaculture in Asia.

ZENOAQ sincerely thanks everyone involved and all the attendees for creating such an enabling event. The ZENOAQ team is looking forward to welcoming you again in Japan.

ZENOAQ announces that its business was not affected by the Typhoon Hagibis that hit Japan on October 12th. We appreciate your concern and all the warm messages.

We would also like to offer our deepest sympathy to all the people affected by the typhoon and we wish everyone a quick recovery.

ZENOAQ has replaced all plastic cushioning materials used for product shipment with paper ones provided by PALTEK, achieving the promotion of plastic-free and high-efficiency logistics operations.

The logistics center that introduced the paper-based packaging system

Currently, there is concern regarding global-scale environmental pollution due to plastic waste; it is one of the major issues on the agenda at the 2019 G20 Osaka Summit, which will be held this month.

ZENOAQ has made efforts to reduce and reuse plastic materials, such as replacing plastic containers for liquid feed additives with paper cartons, and consigning the collection of plastic waste in the offices to recycle companies. Although plastic air pillows were still being used as packing material for products during shipment, Zenoaq found out about an excellent system of paper cushioning materials, called "FillPakⓇ Table Top with Cutter Converter" by Ranpak, and decided to implement it in the company.
Ranpak's Kraft paper for filling excess space in the shipping box is derived from 100% virgin pulp, made from eco-friendly thinned wood cut out from FSC-certified (*) forests. The FillPakⓇ TTC devices set up next to the packing tables convert Kraft paper into a paper-star configuration in order to maximize volume, and dispenses the void-filling material directly into the box at a high speed.
With the introduction of this system, Zenoaq has been able to not only eliminate plastic cushioning materials, but also shorten the time for shipping operations, and significantly reduce material costs. At present, this system is equipped and operated in all company distribution bases.

ZENOAQ continues to strive to create a pleasant environment for humans and animals alike, through the promotion and carrying out of environmentally-friendly activities.

■PALTEK
■Ranpak
*FSC：Forest Stewardship Council

ZENOAQ is proud to announce that it has been accepted as a Corporate Member of HealthforAnimals at the latest Board Meeting and General Assembly held last March.

HealthforAnimals is a not for profit, non-governmental organization representing animal health companies and animal health industry national associations from both developed and developing countries. HealthforAnimals provides value to society by protecting animals and, as a consequence, humans from disease. ZENOAQ is the first Corporate Member from Asia and is represented on the HealthforAnimals Board of Directors by the Company President Mr. Toshikazu Fukui.

■HealthforAnimals

Left : Toshikazu Fukui (President of ZENOAQ)
Right : Mr. Carel du Marchie Sarvaas（Executive Director of HealthforAnimals）

We are very glad to have again had the opportunity of participating at this esteemed event, where we extended successful networking and gained useful market insights into the Animal Health industry. Our sincerest gratitude to all those who spent time with us during the forum. We look forward to meeting you all again in the near future, especially at the Animal Health Innovation Asia forum to be held in Tokyo, Japan on the 6th and 7th of November, 2019.

ZENOAQ has been a regular participant at the Animal Health Innovation Asia event since its inception, and is honored to be the Headline Partner for the 2019 event, which will be held in Tokyo on November 6-7.

Animal Health Innovation Asia is a premier B2B conference showcasing emerging animal health and nutrition companies, from Japan and across the Asia-Pacific, that are actively seeking financial investment or strategic partnership conversations with large corporate firms, investment banks and other funding organizations. It provides guidance veterinary market trends, animal health industry dynamics, insight on how emerging companies are using innovations to prevent disease, and market analysis on M&A activities across the animal health and nutrition markets in Asia.

We hope to see you and your team at the forum in November.

For more information, please visit the official site below.
■ Animal Health Innovation Asia 2019 (Tokyo)

https://animalhealthasia.com

Immunomic Therapeutics announced today that the company has granted ZENOAQ an exclusive license to develop and commercialize its inestigational DNA vaccine, ITI-002, for canine atopic dermatitis and other companion animal allergies.

Active_73957528_1_ITI_Zenoaq_press release.pdf

ZENOAQ actively participated in the 3rd annual Animal Health Innovation Asia forum held in Hong Kong and was also a panelist in the panel discussion entitled "Biotech in Japan" hosted by Mr. Joseph Harvey from Animal Pharm far left in the photo. Other panelists were Dr. Mark Micallef (ZENOAQ) from left, Dr. Yuki Ujimasa, President of AHRMS, Inc. and Prof. Takuya Mizuno from Yamaguchi University. During the discussion, ZENOAQ shared its thoughts and approach on the subject of innovation in biotech in Japan. ZENOAQ sincerely thanks all participants in particular those who asked questions, livening up the panel discussion. The discussion showed that there is great interest in the Animal Health Industry in Japan. The next Animal Health Innovation Asia forum will be held in Tokyo, Japan in November 2019 and we hope to see you there.

Zenoaq is pleased to announce the establishment of its New York branch as of October 1st, 2018. New York office is the 2nd overseas' office for Zenoaq, following the establishment of our Beijing office in 2005.

This is consistent with our intention to expand our presence internationally. In recent years, Zenoaq put biotechnology at the center of its drug discovery development, resulting in our innovative product and the world's first therapeutic product for canine atopic dermatitis applying genetic recombinant technology, "Allermmune® HDM", as well as other pipelines especially in oncology and dermatology. Allermmune® HDM is already commercially available in Japan and South Korea. We look forward to delivering our novel therapeutic solutions to patients around the world in the near future.

With its strategic portfolio, Zenoaq will strive to promote the benefits that animals bring to human beings around the world.

■■Outline of New York office■■
　Name: ZENOAQ New York Branch
　Date of Establishment: October 1, 2018
　Mailing Address: 153 E 110th street #825, New York, NY 10029, USA

ZENOAQ will participate as an exhibitor at the 30th World Buiatrics Congress in Sapporo, Japan from August 28th to September 1st, 2018. Please feel free to drop by ZENOAQ's exhibition booth at the center of the exhibition hall. We are looking forward to meeting you there.

■The 30th WBC in Sapporo
http://www.wbc2018.com/

Our sincerest gratitude to all those who spent time with us during the event, where we extended successful networking and developed useful insights into the Latin American market. We look forward to meeting you all again in the near future.

Nipppon Zenyaku Kogyo co., Ltd., also known as Zenoaq, is pleased to announce that at its recent annual shareholders' meeting held on the 22nd of May in Koriyama City, Japan, it was unanimously decided that Mr. Toshikazu Fukui becomes the new Company President, effective May 22, 2018. Toshikazu Fukui succeeds Keiichi Takano, who was Company President from 2009. Mr. Takano will continue as a Board Member in his new capacity as Corporate Consultant.

Toshikazu Fukui, Nippon Zenyaku Kogyo Co., Ltd. Company President

Brief personal history
1998～2008： Joined Zenoaq General Affairs Department
2008～2011： Division Director of International Business based at the Zenoaq Beijing
　　　　　 　 Representative Office, China
2011～2016： Company President of Nippon Biologicals Inc. [Zenoaq affiliate]
2013～2016： Executive Director of International Business at Zenoaq
2016～ 　　： Company President of Vetoquinol Zenoaq KK.
2016～2018： Executive Vice President
2018～ 　　： Company President

Zenoaq will participate for the first time at the Animal health Innovation LATAM to be held on the 29th and 30th of May in São Paulo.

We are looking forward to participating in this important international event, introducing our company and looking for opportunities to meet with potential partners from around the world at our dedicated meeting area.

We are pleased to announce that the "Animals in Japan (AIJ)" column is back on our company's English language website from this April. The column, contributed by the Animal Literacy Research Institute, provides information on topics of general interest regarding animals in Japan, including relationships between human society and the environments surrounding animals. Articles will appear on the website every three months. We sincerely hope that this site will provide insights into the lives of animals in Japan, and invite everyone to visit our website and read the interesting articles.

ZENOAQ is pleased to announce that as part of its ongoing corporate social responsibility (CSR) activities, it hosted Mr. Martin Paetz, a student at the Technical University of Kaiserslautern in Germany for a period of 3 months from Oct 31st 2017 to Feb 1st 2018 at its Head Office and R&D campus in Koriyama, Fukushima Prefecture.
During his internship training, Martin could experience new skills in biotechnology, especially recombinant protein expression at our laboratories.
Apart from the new technical experiences, Martin could also enjoy various Japanese cultural activities during his stay in Japan. ZENOAQ wishes Martin all the best in his studies and a bright future.

Mr. Martin Paetz (left) with Dr. Mark Micallef, Executive Director of International Business, upon completion of the internship program at ZENOAQ.

ZENOAQ announces the completion of construction of its new QC building within its site in Koriyama City.

[Press_Release] New_QC_building.pdf

Zenoaq will participate in the Animal health Innovation Asia to be held on the 18th and 19th of October in Beijing. Along with Sponsoring the event, Zeonaq will also be giving a presentation pertaining to the status of animal health opportunities and innovation in Japan.

We are looking forward to participating in this important international event, providing our company with a chance to meet with potential partners from Asia and all around the world.

ZENOAQ would like to take this opportunity to congratulate Klifovet on its 20th anniversary, and wishes Klifovet many more years of service to the industry. ZENOAQ was recently invited by Klifovet, a veterinary CRO based in Germany, as a guest speaker during an event in commemoration of Klifovet's 20th anniversary, held in Munich on the 29 and 30 of June, 2017. Dr. Mark Micallef, Executive Director of International Business at ZENOAQ, shared his insights on "Internationalization strategies of an innovative company: A Japanese way". Dr. Micallef also introduced ZENOAQ and the company's potential in the global arena. A warm response was received from the audience and ZENOAQ would like to thank all the participants for their interest, and especially Klifovet's CEO, Dr. Klaus Hellmann for inviting us to this prestigious event.

ZENOAQ was invited as a guest speaker during the Animal Health Investment Europe in London, which was held on 22 and 23 February 2017. Dr. Mark Micallef, Executive Director of International Business, provided updates on the latest trends of the animal health market in Japan. Our sincerest gratitude to all participants for your attendance and interest. Please feel free to contact us via our official company website for more details.

Dr. Mark Micallef, Executive Director of International Business, addressing participants during the forum.

Allermmune® HDM is the first-of-its-kind desensitization therapy (allergen-specific immunotherapy) containing recombinant Der f 2, which is one of the major allergens in house dust mite (HDM)-induced canine atopic dermatitis (cAD).

Allermmune HDM has been proven to be safe and highly effective in clinical studies involving pet dogs diagnosed with HDM-induced cAD and positive for Der f 2 specific serum IgE. This product has been registered and sold in Japan since 2014. Allermmune HDM is expected to be launched in South Korea in April 2017 through our local distributor, ESTIEN Corp.

ZENOAQ announces that its business was not affected by the earthquake that took place this morning (November 22). We appreciate your concern and all the warm messages.

Press Release [Recipient of the Japan Quality Award] ZENOAQ.pdfZENOAQ has been awarded the fiscal year 2016 "Japanese management quality prize (Japan Quality Award)". This is the first time that this award has been awarded to a member of the Japanese veterinary pharmaceutical, livestock and pet industry.

Press Release [Recipient of the Japan Quality Award] ZENOAQ

Japan Quality Award

It has been our pleasure to be invited as a guest speaker during the Animal Health Investment Asia in Hong Kong from 19 - 20 October 2016, where ZENOAQ's Executive Vice President, Mr. Toshikazu Fukui, introduced the animal health market in Japan. As one of the event sponsors, we are proud to have participated in this fruitful event which offered exciting networking opportunities and information exchange among foreign business counterparts, especially those from Asian countries. Kudos to the event organizer and our sincerest gratitude to all participants who were interested in ZENOAQ and the Japanese animal health market. Please feel free to contact us via our official company website for more details.

Zenoaq will join the inaugural Animal Health Investment ASIA to be held on the 19th and 20th of October in Hong Kong. This event presents opportunities for research, commercial and strategic partnerships in Asia and beyond. Zenoaq will also participate as an invited speaker on the animal health market in Japan.
We are glad to have this opportunity to meet with potential partners from Asia and around the world.

http://animalhealthasia.com/

ZENOAQ has successfully exhibited at WCVD8 Bordeaux in France from June 1 to June 4, 2016, promoting our ongoing global epidemiological survey on house dust mite (HDM)-induced canine atopic dermatitis (cAD). Our sincerest gratitude to all who have dropped by our booth and we look forward to sharing more information on ZENOAQ's latest developments with you in the near future.

ZENOAQ will be exhibiting at WCVD8 Bordeaux in France from May 31 to June 4. Please feel free to drop by Booth No. 72. We look forward to meeting you there.

⇒http://www.vetdermbordeaux.com/

Zenoaq and Nexvet Biopharma announced their research and development collaboration has yielded fully caninized, or '100% dog', monoclonal antibodies (mAbs) that bind and potently inhibit the cancer immunotherapy target programmed cell death protein 1 (PD-1).

20160502_press_release_en.pdf

Zenoaq announced that it has signed a Joint - Venture Agreement with Vetoquinol (France) in Japan as of December 3, 2015 to develop, register and market a range of animal health products.

Vetoquinol and Nippon Zenyaku Kogyo Co., LTD Sign a Joint - Venture Agreement in Japan.pdf

LAUNCH OF STEM-CELLBANKER(R) DMSO Free GMP grade.pdf

Zenoaq announced that it has signed a Research and Development Agreement with Nexvet Biopharma (Ireland) as of July 1, 2015 to develop a number of therapeutic biologics for companion animals.

Zenoaq and Nexvet Enter Research and Development Collaboration.pdf

LAUNCH OF STEM-CELLBANKER(R) GMP Grade.pdf

On this occasion, ZENOAQ has been selected as "Best Company in Asia/Australasia 2014"by Animal Pharm.
Animal Pharm is an enterprise based in Britain which analyzes and delivers worldwide information on animal health, medicines and functional materials. An international panel made up of 10 independent individual judges was chosen for the selection of the winning company.
ZENOAQ was selected as "Best Company" based on the development of the next generation hyposensitization therapeutic medicine Allermmune HDM for canine atopic dermatitis, a type of therapy that is expected to satisfy a significant unmet need in canines with house dust mite-induced atopic dermatitis. This is the first in a line of products for immunological ailments in companion animals under development at ZENOAQ.

The original announcement from Animal Pharm can be read by accessing the link below.
https://www.agra-net.net/agra/animal-pharm/business/companies/zenoaq-secures-animal-pharm-award-466970.htm

Being recognized with this Award is the result of the support and cooperation of our valued customers and business partners, to whom we are deeply grateful.
ZENOAQ will continue to strive with our technological skills and knowhow to create new original high-value products and services, for the well-being of animals and all our customers world-wide.

Zenoaq is pleased to announce a new agreement naming Handok Biotech Co., Ltd as our exclusive distributor for the CELLBANKER range of innovative cell freezing media in Korea. Handok Biotech was established in 1991, and is a leading supplier of high quality products and innovative tools for biochemistry, molecular and cell biology research. Handok Biotech is an established distributor of various product brands including BD Biosciences, Eppendorf, Biontex, Innovative Research, and various ELISA kits, in Korea. This partnership is expected to provide our valued customers in Korea with increased access to the unique CELLBANKER range of products.

Nippon Zenyaku Kogyo (ZENOAQ) is pleased to announce the addition of AMS Biotechnology (Europe) Ltd as our distributor for the ZENOAQ range of innovative cell freezing medium "CELLBANKER"series in Europe and North America. AMS Biotechnology (Europe) Ltd is a supplier of research products and custom services for biological and pharmaceutical research with offices in UK, Switzerland and Germany in Europe and California in the States.

We would like to inform you that Nippon Biologicals Inc. has become a subsidiary company of Nippon Zenyaku Kogyo Co., Ltd. effective 30-April, 2009.

We are pleased to inform you that the Board of Directors held on 10, March 2009 have approved the alteration of the President and Representative Director of Nippon Zenyaku Kogyo Co., Ltd.. Former President Mr. Kuniaki Fukui has assumed as the Chairman and Representative Director of Nippon Zenyaku Kogyo Co., Ltd , and Mr. Keiichi Takano has taken over Mr. Fukui fs previous responsibilities as the President and Representative Director as of the 1st of April, 2009. Mr. Takano also holds the post of Director, Domestic Sales Business Unit of the company.

We fd like to make a strong effort to expand our domestic business and overseas business further as an integrated veterinary pharmaceutical company.

1. Assumption of Chairman and Representative Director Kuniaki Fukui

2. Assumption of President and Representative Director Keiichi Takano

3. Effective date 1, April 2009.